Experimental drug tideglusib tested for rare muscle disease
NCT ID NCT02858908
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested a drug called tideglusib in 16 adolescents and adults with a rare muscle disease called myotonic dystrophy type 1. The goal was to see if the drug is safe and if it helps with symptoms. Participants took either 400 mg or 1000 mg of tideglusib daily, and researchers monitored side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle upon Tyne, Tyne and Wear, NE1 4LP, United Kingdom
Conditions
Explore the condition pages connected to this study.